Page last updated: 2024-12-05

iopromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iopromide is a non-ionic, water-soluble contrast agent used in medical imaging, particularly in X-ray procedures. It is a triiodinated benzoic acid derivative, synthesized through a multi-step process involving the coupling of triiodo-substituted benzoic acid with a specific amine. Iopromide is administered intravenously and rapidly distributes throughout the body, accumulating in tissues and organs with high water content, thereby enhancing their visibility on X-ray images. Its non-ionic nature contributes to its low toxicity and fewer side effects compared to ionic contrast agents. Iopromide is widely used in various diagnostic procedures, such as computed tomography (CT) scans, angiography, and myelography, aiding in the diagnosis of a wide range of medical conditions. Its ability to enhance contrast and visualization of internal structures makes it an indispensable tool for medical imaging and diagnosis.'

iopromide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3736
CHEMBL ID1725
CHEBI ID63578
SCHEMBL ID24546
SCHEMBL ID23673810
MeSH IDM0115091

Synonyms (114)

Synonym
AC-535
MLS002154045
smr001233368
n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-n-methyl-5-{[(methyloxy)acetyl]amino}benzene-1,3-dicarboxamide
iopromide
PRESTWICK2_000872
BPBIO1_001039
iopromidum [inn-latin]
1,3-benzenedicarboxamide, n,n'-bis(2,3-dihydroxypropyl)-5-((methoxyacetyl)amino)-n-methyl-2,4,6-triiodo-
n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-n-methylisophthalamide
ultravist
brn 7085608
einecs 277-385-9
zk 35760
iopromida [inn-spanish]
shl 414c
1,3-benzenedicarboxamide, n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-((methoxyacetyl)amino)-n-methyl-
NCGC00016923-01
cas-73334-07-3
NCGC00179367-01
BSPBIO_000943
PRESTWICK3_000872
AB00513942
proscope (tn)
73334-07-3
ultravist (tn)
iopromide (jan/usp/inn)
D01893
PRESTWICK0_000872
PRESTWICK1_000872
SPBIO_002864
proscope
chebi:63578 ,
zk-35760
CHEMBL1725
HMS1570P05
magnesium methanide propan-1-ide(1:1:1)
1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-3-n-methylbenzene-1,3-dicarboxamide
n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-n-methylisophthalamide
HMS2097P05
lopromid
ultravist 300
iopromid
ultravist (pharmacy bulk)
iopromide [usan:usp:inn:ban]
bay 86-4877
712bac33mz ,
iopromidum
ultravist 300 in plastic container
bay86-4877
unii-712bac33mz
ultravist 370
ultravist 240
iopromida
ultravist 150
tox21_110684
dtxsid0023163 ,
dtxcid503163
HMS2233O23
S3207
c18h24i3n3o8
FT-0627283
HMS3370M05
iopromide [mi]
iopromide [mart.]
iopromide [ep impurity]
iopromide [usan]
iopromide [who-dd]
iopromide [orange book]
iopromide [ep monograph]
iopromide [inn]
iopromide [jan]
iopromide [usp-rs]
iopromide [vandf]
iopromide [usp monograph]
CCG-220872
DGAIEPBNLOQYER-UHFFFAOYSA-N
SCHEMBL24546
tox21_110684_1
NCGC00179367-03
n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-n1-methylisophthalamide
AKOS025402129
DB09156
n-(2,3-dihydroxypropyl)-3-[(2,3-dihydroxypropyl)(methyl)carbamoyl]-5-[(1-hydroxy-2-methoxyethylidene)amino]-2,4,6-triiodobenzene-1-carboximidic acid
sr-01000841262
SR-01000841262-2
iopromide, united states pharmacopeia (usp) reference standard
iopromide, analytical standard
iopromide, european pharmacopoeia (ep) reference standard
iopromide for system suitability 2, european pharmacopoeia (ep) reference standard
iopromide for system suitability 1, european pharmacopoeia (ep) reference standard
HMS3714P05
HY-B1362
CS-0013103
iopromid 100 microg/ml in acetonitrile
BCP08449
Q4202805
BS-17441
mfcd00867924
EN300-19767813
n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-n1-methylbenzene-1,3-dicarboxamide
SCHEMBL23673810
iopromide (usan:usp:inn:ban)
iopromida (inn-spanish)
iopromidum (inn-latin)
iopromide (mart.)
iopromide (usp-rs)
iopromide (ep monograph)
n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-((methoxyacetyl)amino)-n-methylisophthalamide
iopromide (ep impurity)
v08ab05
iopromide (usp monograph)
1,3-benzenedicarboxamide, n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-n1-methyl-
Z2681890595

Research Excerpts

Overview

Iopromide is a nonionic, iodinated, monomeric, radiographic contrast agent used in various indications, including coronary angiography and visceral and peripheral arteriography. It exhibits low osmolality and low viscosity in high concentration in aqueous solutions.

ExcerptReferenceRelevance
"Iopromide is an X-ray and MRI contrast agent that is virtually non-biodegradable and persistent through typical wastewater treatment processes. "( Biodegradability of iopromide products after UV/H₂O₂ advanced oxidation.
Aga, DS; Keen, OS; Linden, KG; Love, NG, 2016
)
2.2
"Iopromide was shown to be a well-tolerated contrast agent whose usage resulted in high image quality. "( Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE).
Heinsohn, C; Kwon, ST; Lengsfeld, P; Liang, CH; Palkowitsch, P; Stauch, K; Zhang, SX, 2012
)
2.09
"Iopromide is an X-ray contrast agent that has been detected frequently in effluents of wastewater treatment plants and in surface waters due to its persistence and high usage."( Structural characterization of metabolites of the X-ray contrast agent iopromide in activated sludge using ion trap mass spectrometry.
Aga, DS; Celiz, MD; Eichhorn, P; Pérez, S, 2006
)
1.29
"Iopromide is a new nonionic contrast medium that has been extensively studied for both intravenous (i.v.) and intraarterial indications."( A double-blind study of iopromide 300 for peripheral arteriography. Results of a multi-institutional comparison of iopromide with iohexol and iopamidol.
Bettmann, MA; Druy, EM; Jeans, W, 1994
)
1.32
"Iopromide is a nonionic monomeric contrast agent. "( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
2.04
"Iopromide is a new monomeric, nonionic contrast agent that exhibits low osmolality and low viscosity in high concentration in aqueous solutions. "( A comparison of iopromide with iopamidol and iohexol for contrast-enhanced computed tomography.
Abrahams, J; Bernardino, M; Brunetti, J; Drayer, BP; Goldberg, SN; Golding, S, 1994
)
2.08
"Iopromide is a new nonionic monomeric contrast medium for cerebral arteriography. "( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
2.04
"Iopromide is a nonionic, iodinated, monomeric, radiographic contrast agent used in various indications, including coronary angiography and visceral and peripheral arteriography. "( Inhibition of thrombin by iopromide in vitro.
Graf, LL; Hinderling, PH; Jacob, GB; Kressin, DC; Marlar, RA; Young, DA, 2001
)
2.05
"Iopromide proved itself to be an x-ray contrast medium with a low rate of side effects, which can be effectively eliminated from the body by means of conventional dialysis."( Elimination of the nonionic contrast medium iopromide in end-stage renal failure by hemodialysis.
Hollmann, HJ; Kierdorf, H; Kindler, J; Speck, U; Vorwerk, D; Winterscheid, R, 1989
)
1.26
"Iopromide 300 is a good candidate for this examination, on the basis of the safety and efficacy evaluated in this study."( [Conventional cerebral arteriography. Study of a new non-ionic contrast medium: iopromide 300].
Kasbarian, M, 1989
)
1.23

Effects

ExcerptReferenceRelevance
"Iopromide has an efficacy, safety, and tolerance profile comparable to that of iopamidol and iohexol at 300 mg I/mL for head and body CECT. "( A comparison of iopromide with iopamidol and iohexol for contrast-enhanced computed tomography.
Abrahams, J; Bernardino, M; Brunetti, J; Drayer, BP; Goldberg, SN; Golding, S, 1994
)
2.08
"Iopromide has an efficacy, safety, and tolerance profile comparable to that of iopamidol and iohexol at 300 mg I/mL for head and body CECT. "( A comparison of iopromide with iopamidol and iohexol for contrast-enhanced computed tomography.
Abrahams, J; Bernardino, M; Brunetti, J; Drayer, BP; Goldberg, SN; Golding, S, 1994
)
2.08

Toxicity

iopromide and iodixanol, two kinds of representative non-ionic CM, were used for the in vivo study. Minor adverse clinical experiences were noted in 23% of the iopromid group versus 20% of a comparator group.

ExcerptReferenceRelevance
" Adverse reactions were sought, physical examinations were performed, and standard hematology and serum chemistry values were measured before and 1 day after injection; a 72-hour serum creatinine level was also measured."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.6
" Mild adverse reactions were experienced by 10% of patients; there were no significant differences in reaction rates among contrast agents."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.6
"Iopromide at a dose of approximately 300 mg I/kg is safe and effective as an excretory urographic agent and is comparable in performance with ioversol and iopamidol."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
2.04
" Adverse events were monitored by investigators, and efficacy was evaluated by grading the radiographic images."( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
0.6
"Most adverse events were mild or moderate in severity; all resolved completely."( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
0.6
"These study results indicate that iopromide is a safe and effective contrast medium for cerebral angiography."( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
0.88
" Minor adverse clinical experiences were noted in 23% of the iopromide group versus 20% of the comparator group."( Double-blind study of the safety, tolerance, and diagnostic efficacy of iopromide as compared with iopamidol and iohexol in patients requiring aortography and visceral angiography.
Athanasoulis, C; Bron, K; Cope, C; Druy, EM; Faykus, MH; Hedgcock, M; Miller, FJ, 1994
)
0.76
" Outcome variables were pain, image quality and adverse events."( [Contrast media in peripheral angiography: does cost reduction mean loss of quality and safety? A reevaluation based on a randomized double-blind comparative study of ioxaglate versus iopromide].
Farres, MT; Lammer, J; Thurnher, S; Wildling, R; Winkelbauer, F; Woessmer, B, 1996
)
0.49
" Mild adverse events were observed more frequently in ioxaglate angiography (11% vs."( [Contrast media in peripheral angiography: does cost reduction mean loss of quality and safety? A reevaluation based on a randomized double-blind comparative study of ioxaglate versus iopromide].
Farres, MT; Lammer, J; Thurnher, S; Wildling, R; Winkelbauer, F; Woessmer, B, 1996
)
0.49
" However, an increase of mild adverse reactions up to 11% to 15% has to be accepted."( [Contrast media in peripheral angiography: does cost reduction mean loss of quality and safety? A reevaluation based on a randomized double-blind comparative study of ioxaglate versus iopromide].
Farres, MT; Lammer, J; Thurnher, S; Wildling, R; Winkelbauer, F; Woessmer, B, 1996
)
0.49
" Regarding iodinated contrast media (CM), LD50 tests were used extensively in the past."( Preclinical safety assessment of contrast media: predictive value.
Karlsson, JO, 1996
)
0.29
" Specifically, frequency of adverse events (AEs), subjective change in quality of diagnostic information, and quantitative enhancement characteristics were compared."( Iopentol (Imagopaque 300) compared with iopromide (Ultravist 300) in abdominal CT. A multi-centre monitoring trial assessing adverse events and diagnostic information--results from 518 patients in Spain.
Encina, JL; Martí-Bonmatí, L; Rodríguez, V; Ronchera-Oms, CL, 1997
)
0.56
" ECG, blood pressure, heart rate, adverse events and efficacy were evaluated."( Iopentol (Imagopaque 300) compared with iopromide (Ultravist 300) in pediatric angiocardiography. A clinical trial assessing adverse events, ECG and diagnostic information.
Aggoun, Y; Iserin, L; Kachaner, J; Piéchaud, JF; Skinningsrud, K, 1997
)
0.56
"Iodixanol 270 mg I/ml causes significantly less injection-associated pain during femoral arteriography and is as safe and efficacious as iopromide 300 mg I/ml."( Injection-associated pain in femoral arteriography: a European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide.
Downes, M; Grynne, BH; Justesen, P; Lang, H; Rasch, W; Seim, E,
)
0.53
"Most studies of the adverse effects of x-ray contrast media used in ERCP have focused on post-ERCP pancreatitis."( Comparative cytotoxicity of low-osmolar nonionic and high-osmolar ionic contrast media to dog gallbladder epithelial cells.
Ju, YM; Kim, JY; Kim, MH; Lee, SK; Min, YI; Seo, DW, 2002
)
0.31
"For 2 years, we prospectively recorded all adverse events temporally associated with the administration of iopromide in 29,508 consecutive patients undergoing contrast-enhanced CT at our institution."( Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital.
Mortelé, KJ; Oliva, MR; Ondategui, S; Ros, PR; Silverman, SG, 2005
)
0.54
" One hundred eighty-eight adverse events (89%) were rated mild, 19 moderate (9%), and four severe (2%), including one fatality."( Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital.
Mortelé, KJ; Oliva, MR; Ondategui, S; Ros, PR; Silverman, SG, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"To prospectively evaluate adverse events (AEs) in patients who underwent nonionic monomeric or dimeric contrast media-enhanced computed tomography (CT) and to compare these effects with AEs in patients who underwent unenhanced CT."( Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial.
Böhm, I; Hübner-Steiner, U; Kuhl, CK; Schild, HH; Speck, U, 2006
)
0.33
" Both contrast agents were safe in that no severe AEs and only a few moderate AEs were observed."( Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial.
Böhm, I; Hübner-Steiner, U; Kuhl, CK; Schild, HH; Speck, U, 2006
)
0.33
"Exposure to iodinated contrast media may elicit a variety of adverse reactions."( Iodide mumps after contrast media imaging: a rare adverse effect to iodine.
Bircher, AJ; Gilgen-Anner, Y; Heim, M; Ledermann, HP, 2007
)
0.34
" The important role of iodine in this adverse reaction is demonstrated."( Iodide mumps after contrast media imaging: a rare adverse effect to iodine.
Bircher, AJ; Gilgen-Anner, Y; Heim, M; Ledermann, HP, 2007
)
0.34
" The secondary endpoints are absolute and relative increases in sCr of at least 50%, thrombolysis in myocardial infarction (TIMI) perfusion grade, and major adverse cardiac events at 1, 6, and 12 months."( The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Limbruno, U; Picchi, A; Pierli, C, 2010
)
0.36
" It is a safe procedure and more cost effective than a negative exploration or diagnostic laparoscopy."( Is herniography useful and safe?
Hureibi, KA; Kidambi, AV; McLatchie, GR, 2011
)
0.37
" To assess the toxic effects of non-ionic CM on the glomerular and aortic endothelial cells, iopromide and iodixanol, two kinds of representative non-ionic CM, were used for the in vivo study."( Toxic effects of a high dose of non-ionic iodinated contrast media on renal glomerular and aortic endothelial cells in aged rats in vivo.
Chen, B; Chen, L; Jia, E; Jia, Q; Li, C; Tao, Z; Wang, L; Xu, Z; Yang, Z; Zhao, Y; Zhu, T, 2011
)
0.59
"8%) patients, there were reports of adverse drug reactions (ADRs) excluding tolerance indicators (TIs) (i."( Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE).
Heinsohn, C; Kwon, ST; Lengsfeld, P; Liang, CH; Palkowitsch, P; Stauch, K; Zhang, SX, 2012
)
0.65
"49%) reported an adverse drug reaction (ADR) and 1983 patients (1."( Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients.
Bostelmann, S; Lengsfeld, P; Palkowitsch, PK, 2014
)
0.7
"The purpose of the study is to examine the incidence of adverse reactions caused by non-ionic contrast media in selected patients after desensitization treatment and to evaluate the safety profile of organ iodine contrast media (i."( Safety profile and protocol prevention of adverse reactions to uroangiographic contrast media in diagnostic imaging.
Brunese, L; D'Amora, M; D'Andrea, A; Di Grezia, G; Grassi, R; Mandato, Y; Reginelli, A; Rossi, C; Rotondi, A,
)
0.13
"The novel DEB is safe and has a favorable vascular healing response on neointimal hyperplasia."( Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis.
An, X; Du, R; Han, H; Ni, J; Ying, C; Zhang, J; Zhang, R; Zhu, J; Zhu, Z, 2015
)
0.7
"The relative incidence of long-term adverse effects between low-osmolar contrast media (LOCM) and iso-osmolar contrast media (IOCM) after coronary angiography is still unclear."( Long-Term Adverse Effects of Low-Osmolar Compared With Iso-Osmolar Contrast Media After Coronary Angiography.
Chang, D; Ju, S; Lu, CQ; Tang, A; Wang, YC; Zhang, SJ, 2016
)
0.43
"The presence of iodinated X-ray contrast media (ICM) in source waters is of high concern to public health because of their potential to generate highly toxic disinfection by-products (DBPs)."( The impact of iodinated X-ray contrast agents on formation and toxicity of disinfection by-products in drinking water.
Duirk, SE; Jeong, CH; Machek, EJ; Plewa, MJ; Richardson, SD; Shakeri, M; Ternes, TA; Wagner, ED, 2017
)
0.46
" Intravenous provocation with a skin test-negative RCM is safe and enables identification of a tolerated alternative RCM."( Radiocontrast Media Hypersensitivity: Skin Testing Differentiates Allergy From Nonallergic Reactions and Identifies a Safe Alternative as Proven by Intravenous Provocation.
Behle, V; Brockow, K; Stoevesandt, J; Trautmann, A,
)
0.13
" We used reports downloaded from the US Food and Drug Administration Adverse Event Reporting System and data on the national use of individual ICM for this analysis."( Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Lin, W; Lin, X; Weng, L; Yang, J, 2023
)
0.91
"A total of 11,343,365 adverse event reports were collected from the first quarter of 2013 to the first quarter of 2021, among which 5,432 cases were identified as ICM-induced HSRs."( Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Lin, W; Lin, X; Weng, L; Yang, J, 2023
)
0.91

Pharmacokinetics

iopromide 240 is almost completely excreted renally within 72 hours, with a prolonged half-life as a result of the route of administration. The terminal disposition phase half- life of iopromides was 2 h and 1.5 h.

ExcerptReferenceRelevance
"Four nonionic contrast media (iohexol, iopamidol, iopromide, and iosimide) are compared in this clinical study in their pharmacokinetic behavior with an ionic reference preparation (meglumine diatrizoate)."( Pharmacokinetics of iohexol, iopamidol, iopromide, and iosimide compared with meglumine diatrizoate.
Hartwig, P; Mützel, W; Taenzer, V, 1989
)
0.8
" These data were used to calculate pharmacokinetic parameters such as half-lives, mean residence times, and areas under the curve with a computer program."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
" The computer program allowed for excellent fitting curves to the measured attenuation values and for subsequent calculation of pharmacokinetic parameters."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
"The pharmacokinetic parameters evaluated might be useful in the optimization of dosing and scanning parameters of the abdomen for ultrafast and helical CT."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
" The results were subject to pharmacokinetic analysis using compartment model-independent and -dependent methods."( Pharmacokinetics and tolerability of iopromide 240 after lumbar myelography.
Krause, W; Kugoev, AI; Timerbaeva, SL; Wegener, R, 1999
)
0.58
"After lumbar myelography, iopromide 240 is almost completely excreted renally within 72 hours, with a prolonged half-life as a result of the route of administration."( Pharmacokinetics and tolerability of iopromide 240 after lumbar myelography.
Krause, W; Kugoev, AI; Timerbaeva, SL; Wegener, R, 1999
)
0.88
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Therefore, the pharmacokinetic properties of the CA possess a central role: iodinated x-ray CAs are small molecules that distribute rapidly within the extravascular extracellular space, whereas larger macromolecular compounds have a prolonged vascular phase and a restricted volume of distribution."( Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics.
Grenacher, L; Jost, G; Pietsch, H, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
"RA monitoring combined with spontaneous respiration to trigger image acquisition in CTPA produces optimal contrast enhancement in pulmonary arterial structures with minimal venous filling even with reduced doses of CA."( Optimizing computed tomography pulmonary angiography using right atrium bolus monitoring combined with spontaneous respiration.
Li, J; Li, W; Lun-Hou, D; Wang, M; Zhai, R, 2015
)
0.42
"To evaluate the feasibility of CT angiography of lower extremities by using 100 kVp as tube voltage and Iodixanol(270 mg I/ml) as contrast medium combined with iDose(4) iterative reconstruction technique."( [Applied research of CT angiography of lower extremities by using 100 kVp and iodixanol(270 mg I/ml) combined with iDose(4) iterative reconstruction technique].
Chen, B; Cheng, J; He, H; Kong, Q; Xiong, S; Xu, L; Xu, X; Yan, Z, 2015
)
0.42
"Using 100 kVp and Iodixanol (270 mg I/ml) combined with iDose(4) -4 iterative reconstruction technique for CT angiography of lower extremities, the image quality could meet the requirement for clinical diagnosis, the radiation dose and the volume of contrast medium could be lowered."( [Applied research of CT angiography of lower extremities by using 100 kVp and iodixanol(270 mg I/ml) combined with iDose(4) iterative reconstruction technique].
Chen, B; Cheng, J; He, H; Kong, Q; Xiong, S; Xu, L; Xu, X; Yan, Z, 2015
)
0.42
"The study aimed to prospectively evaluate the radiation dose reduction potential and image quality (IQ) of a high-concentration contrast media (HCCM) injection protocol in combination with a low tube current (mAs) in coronary computed tomography angiography."( Evaluation of a High Concentrated Contrast Media Injection Protocol in Combination with Low Tube Current for Dose Reduction in Coronary Computed Tomography Angiography: A Randomized, Two-center Prospective Study.
Hua, Y; Jin, X; Li, C; Mao, D; Shi, K; Sun, Y; Wang, M; Xu, J, 2017
)
0.46
"HCCM combined with low tube current allows dose reduction in coronary computed tomography angiography and does not compromise IQ."( Evaluation of a High Concentrated Contrast Media Injection Protocol in Combination with Low Tube Current for Dose Reduction in Coronary Computed Tomography Angiography: A Randomized, Two-center Prospective Study.
Hua, Y; Jin, X; Li, C; Mao, D; Shi, K; Sun, Y; Wang, M; Xu, J, 2017
)
0.46
"BACKGROUND This study is to investigate the feasibility of low iodine concentration contrast material (CM) combined with low tube voltage and adaptive statistical iterative reconstruction (ASIR) in renal computed tomography angiography (CTA)."( Low-Dose Scanning Technology Combined with Low-Concentration Contrast Material in Renal Computed Tomography Angiography (CTA): A Preliminary Study.
Fan, J; He, J; Li, W; Liu, S; Sheng, H; Shi, H; Sun, H, 2017
)
0.46
"To investigate the feasibility of iterative model reconstruction (IMR) combined with low tube voltage, low iodine load, and low iodine deliver rate in craniocervical computed tomography angiography (CTA)."( Feasibility study of iterative model reconstruction combined with low tube voltage, low iodine load, and low iodine delivery rate in craniocervical CT angiography.
Cai, W; Cheng, B; Gong, J; Hu, C; Hu, S; Shi, D; Wang, X; Zhang, W, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" DCBs carry an active drug and a nonpolymeric carrier molecule or excipient that enhance the bioavailability of the drug to the vessel wall."( Drug-coated percutaneous balloon catheters.
Betala, JV; LaBerge, M; Langan Iii, EM, 2014
)
0.4
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol. Compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.

ExcerptRelevanceReference
" An increase of the dosage resulted in a statistically significant improvement of the quality of the radiographic visualization."( Iopromide dosage and urographic image quality: is there an optimal dose?
Dominik, R; Keysser, R; Taenzer, V, 1989
)
1.72
"9 months) in 52 patients with hepatocellular carcinoma (HCC): An emulsion of Lipiodol and epirubicin was injected as selectively as possible in a dosage proportional to liver function and tumour size."( [The chemoembolization of hepatocellular carcinoma: the computed tomographic findings and clinical results in prospective repetitive therapy].
Brambs, HJ; Claussen, CD; Dette, S; Dietz, K; Duda, SH; Geissler, F; Huppert, PE; Lauchart, W, 1994
)
0.29
" The contrast medium was injected rapidly into an antecubital vein within 2-3 min in most cases, using a standard dosage of 1 ml kg-1 body weight."( Iomeprol versus iopromide for intravenous urography.
de Geeter, P; Melchior, H, 1994
)
0.63
" New dosage regimens also could be simulated successfully."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
"The pharmacokinetic parameters evaluated might be useful in the optimization of dosing and scanning parameters of the abdomen for ultrafast and helical CT."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
" However, the relatively high radiation dosage of an additional CTP requires a strict indication regiment in patients with a negative CTA."( [A differentiated approach to the diagnosis of pulmonary embolism and deep venous thrombosis using multi-slice CT].
Günther, RW; Haage, P; Mahnken, AH; Schaller, S; Sinha, AM; Stargardt, A; Wildberger, JE, 2002
)
0.31
" The data clearly show that the ozonation of iopromide using a common applied ozone dosage leads to the formation of numerous iodinated transformation products, which are detectable by LC-ESI-MS."( Ozonation and reductive deiodination of iopromide to reduce the environmental burden of iodinated X-ray contrast media.
Jekel, M; Miehe, U; Putschew, A; Tellez, AS, 2007
)
0.87
" After the mask image had been taken, the contrast medium was administered using a dosage of 1ml/kg body weight at a rate of 4ml/s."( Evaluation of contrast-enhanced digital mammography.
Bick, U; Diekmann, F; Diekmann, S; Fallenberg, EM; Fischer, T; Freyer, M; Pöllinger, A, 2011
)
0.37
"The aim of this research was to study the gastrointestinal transit and gastric emptying of non-disintegrating solid dosage forms in rats using X-ray imaging."( Gastro intestinal tracking and gastric emptying of solid dosage forms in rats using X-ray imaging.
Brandeis, R; Karton, Y; Rosner, A; Saphier, S, 2010
)
0.36
" This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis."( Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.
Abtahi, S; Ajami, G; Amoozgar, H; Basiratnia, M; Borzouee, M; Cheriki, S; Derakhshan, A; Mohamadi, M; Soltani, M, 2010
)
0.58
" So HR, gender, TCD and weight can be used to adjust flow rate and dosage of contrast media before administration of contrast media during coronary CT angiography."( Factors influencing delay time and coronary arterial density during coronary angiography with DSCT.
Dogra, V; Tang, J; Tang, L; Wang, D; Xu, H; Xu, Y; Yu, T; Zhu, X, 2011
)
0.37
" Subsequently, Han Wistar rats (8 per group) received an intravenous injection of iso-osmolar CA (iodixanol) or low-osmolar CA (iopromide) at a dosage of 4 gI/kg body weight."( Changes of renal water diffusion coefficient after application of iodinated contrast agents: effect of viscosity.
Hütter, J; Jost, G; Lengsfeld, P; Lenhard, DC; Pietsch, H; Sieber, MA, 2011
)
0.57
" Only one patient showed renal failure, one week after dosing with iodixanol."( Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
Chen, Y; Fu, G; Gao, C; Gao, W; He, B; He, Q; Hu, S; Liu, H; Liu, S; Liu, Y; Qi, X; Qiu, C; Su, X; Wang, J; Wang, L; Wang, M; Yang, P; Zhao, R; Zheng, X; Zheng, Y; Zhou, S, 2012
)
0.69
" CM dosage calculation was randomly categorized into groups: a BW group and a BW-BMI group."( Dual-source CT coronary angiography involving injection protocol with iodine load tailored to patient body weight and body mass index: estimation of optimal contrast material dose.
Tang, L; Xu, H; Xu, Y; Yang, G; Zhu, X; Zhu, Y, 2013
)
0.39
" The CAs were administered intravenously at a dosage of 4 g iodine/kg body weight."( The effect of iodinated contrast agent properties on renal kinetics and oxygenation.
Frisk, AL; Jost, G; Lengsfeld, P; Lenhard, DC; Pietsch, H, 2013
)
0.39
" The trial dosed with strain I-24 showed better IOPr removal than the un-dosed one."( Isolation and identification of an iopromide-degrading strain and its application in an A2/O system.
Gao, P; He, J; Hu, J; Liu, K; Liu, Y; Ognier, S; Xu, B; Xue, G, 2013
)
0.67
" On the basis of phantom measurements for the low-kilovolt CTA protocols, the iodine dosage was adjusted to 150 mg iodine/kg (70 kV) and 210 mg iodine/kg (90 kV)."( Optimizing contrast media injection protocols in state-of-the art computed tomographic angiography.
Flohr, TG; Jost, G; Korporaal, JG; Lell, MM; Mahnken, AH; Pietsch, H; Uder, M, 2015
)
0.42
" However, determining the precise dosage for satisfactory efficacy and few side effects are still challenging."( A new method for using radiopaque sclerosing foam to treat venous malformations.
Chen, AW; Li, K; Liu, SH; Liu, YR, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
radioopaque mediumA substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays.
nephrotoxic agentA role played by a chemical compound exihibiting itself through the ability to induce damage to the kidney in animals.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
dicarboxylic acid diamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency316.22800.031637.5844354.8130AID743255
farnesoid X nuclear receptorHomo sapiens (human)Potency0.37580.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency12.58930.005428.02631,258.9301AID1346985
importin subunit beta-1 isoform 1Homo sapiens (human)Potency29.09295.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency29.09295.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency29.09295.804816.996225.9290AID540253
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (91)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,454)

TimeframeStudies, This Drug (%)All Drugs %
pre-199059 (4.06)18.7374
1990's216 (14.86)18.2507
2000's417 (28.68)29.6817
2010's719 (49.45)24.3611
2020's43 (2.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.07 (24.57)
Research Supply Index7.54 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index91.04 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials219 (13.24%)5.53%
Reviews30 (1.81%)6.00%
Case Studies128 (7.74%)4.05%
Observational8 (0.48%)0.25%
Other1,269 (76.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]